<DOC>
	<DOC>NCT02516579</DOC>
	<brief_summary>In the context of the Risk Management Plan (RMP), as requested from Addmedica by the EMEA, to collect information about long-term safety of Siklos® (hydroxycarbamide) when used in current practices for the prevention of symptomatic vaso-occlusive complications in patients with Sickle Cell Disease.</brief_summary>
	<brief_title>European Sickle Cell Disease Cohort - Hydroxyurea</brief_title>
	<detailed_description />
	<mesh_term>Anemia, Sickle Cell</mesh_term>
	<mesh_term>Hydroxyurea</mesh_term>
	<criteria>Male or female ambulatory patients, aged 2 years and more (children, adolescents or adults) With symptomatic sickle cell syndrome Justifying a treatment with Siklos® according to the product indications Having been informed of the study by the initiating physician and consenting to participate to the cohort.</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>